Carregant...
Who funds Alzheimer's disease drug development?
INTRODUCTION: Despite the increase in Alzheimer's disease (AD) cases in the United States, no new treatments have been approved in the United States since 2003. The costs associated with drug development programs are high and serve as a significant deterrent to AD therapeutic investigations. In...
Guardat en:
| Publicat a: | Alzheimers Dement (N Y) |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8145442/ https://ncbi.nlm.nih.gov/pubmed/34095442 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/trc2.12185 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|